This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hildreth, J. E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hildreth, J. E. K.

 Previous Article  |  Next Article 

Journal of Virology, December 1998, p. 9544-9552, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Syncytium-Inhibiting Monoclonal Antibodies Produced against Human T-Cell Lymphotropic Virus Type 1-Infected Cells Recognize Class II Major Histocompatibility Complex Molecules and Block by Protein Crowding

James E. K. Hildreth*

Leukocyte Immunochemistry Laboratory, Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Received 16 July 1998/Accepted 11 September 1998

Four new monoclonal antibodies (MAbs) that inhibit human T-cell lymphotropic virus type 1 (HTLV-1)-induced syncytium formation were produced by immunizing BALB/c mice with HTLV-1-infected MT2 cells. Immunoprecipitation studies and binding assays of transfected mouse cells showed that these MAbs recognize class II major histocompatibility complex (MHC) molecules. Previously produced anti-class II MHC antibodies also blocked HTLV-1-induced cell fusion. Coimmunoprecipitation and competitive MAb binding studies indicated that class II MHC molecules and HTLV-1 envelope glycoproteins are not associated in infected cells. Anti-MHC antibodies had no effect on human immunodeficiency virus type 1 (HIV-1) syncytium formation by cells coinfected with HIV-1 and HTLV-1, ruling out a generalized disruption of cell membrane function by the antibodies. High expression of MHC molecules suggested that steric effects of bound anti-MHC antibodies might explain their inhibition of HTLV-1 fusion. An anti-class I MHC antibody and a polyclonal antibody consisting of several nonblocking MAbs against other molecules bound to MT2 cells at levels similar to those of class II MHC antibodies, and they also blocked HTLV-1 syncytium formation. Dose-response experiments showed that inhibition of HTLV-1 syncytium formation correlated with levels of antibody bound to the surface of infected cells. The results show that HTLV-1 syncytium formation can be blocked by protein crowding or steric effects caused by large numbers of immunoglobulin molecules bound to the surface of infected cells and have implications for the structure of the cellular HTLV-1 receptor(s).

* Mailing address: Department of Pharmacology and Molecular Sciences, Biophysics Bldg., Rm. 311, Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD 21205. Phone: (410) 955-3017. Fax: (410) 955-1894. E-mail: jhildret{at}jhmi.edu.

Journal of Virology, December 1998, p. 9544-9552, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gould, S. J., Booth, A. M., Hildreth, J. E. K. (2003). The Trojan exosome hypothesis. Proc. Natl. Acad. Sci. USA 100: 10592-10597 [Abstract] [Full Text]  
  • Nath, M. D., Ruscetti, F. W., Petrow-Sadowski, C., Jones, K. S. (2003). Regulation of the cell-surface expression of an HTLV-I binding protein in human T cells during immune activation. Blood 101: 3085-3092 [Abstract] [Full Text]  
  • Gatot, J.-S., Callebaut, I., Van Lint, C., Demonte, D., Kerkhofs, P., Portetelle, D., Burny, A., Willems, L., Kettmann, R. (2002). Bovine Leukemia Virus SU Protein Interacts with Zinc, and Mutations within Two Interacting Regions Differently Affect Viral Fusion and Infectivity In Vivo. J. Virol. 76: 7956-7967 [Abstract] [Full Text]  
  • Brighty, D. W., Jassal, S. R. (2001). The Synthetic Peptide P-197 Inhibits Human T-Cell Leukemia Virus Type 1 Envelope-Mediated Syncytium Formation by a Mechanism That Is Independent of Hsc70. J. Virol. 75: 10472-10478 [Abstract] [Full Text]  
  • Jassal, S. R., Pohler, R. G., Brighty, D. W. (2001). Human T-Cell Leukemia Virus Type 1 Receptor Expression among Syncytium-Resistant Cell Lines Revealed by a Novel Surface Glycoprotein-Immunoadhesin. J. Virol. 75: 8317-8328 [Abstract] [Full Text]  
  • Niyogi, K., Hildreth, J. E. K. (2001). Characterization of New Syncytium-Inhibiting Monoclonal Antibodies Implicates Lipid Rafts in Human T-Cell Leukemia Virus Type 1 Syncytium Formation. J. Virol. 75: 7351-7361 [Abstract] [Full Text]  
  • Okuma, K., Matsuura, Y., Tatsuo, H., Inagaki, Y., Nakamura, M., Yamamoto, N., Yanagi, Y. (2001). Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins. J. Gen. Virol. 82: 821-830 [Abstract] [Full Text]  
  • Sommerfelt, M. A. (1999). Retrovirus receptors. J. Gen. Virol. 80: 3049-3064 [Full Text]  
  • Wilson, K. A., Maerz, A. L., Poumbourios, P. (2001). Evidence That the Transmembrane Domain Proximal Region of the Human T-cell Leukemia Virus Type 1 Fusion Glycoprotein gp21 Has Distinct Roles in the Prefusion and Fusion-activated States. J. Biol. Chem. 276: 49466-49475 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»